Affimed N.V.
AFMDQ Healthcare Biotechnology
Affimed N.V.’s revenue for fiscal 2023 (year ended December 2023) was $9.0 million, down 79.4% from fiscal 2022.
Follow AFMDQ
Affimed N.V. (AFMDQ) EV/Sales
As of 16 October 2026, Affimed N.V. (AFMDQ) trades at a EV/Sales of −19.2×. Over the past ten years it has ranged from −20.4× (June 2018) to 68.8× (July 2015); the current reading is higher than 12% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 3.1× | — |
| FY2022 | −3.8× | — |
| FY2022 | 9.7× | — |
| FY2021 | −3.1× | — |
| FY2021 | −3.6× | — |
| FY2020 | −3.7× | — |
| FY2020 | −4.0× | — |
| FY2019 | −4.0× | — |
| FY2019 | −3.7× | — |
| FY2018 | −3.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 36.7× | 96.09% |
| Jun 2024 | 18.7× | 47.92% |
| Mar 2024 | 12.7× | 310.12% |
| Dec 2023 | 3.1× | — |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AFMDQ Affimed N.V. | −19.2× |
| VIVS VivoSim Labs, Inc. compare | −7.4× |
| ONCO Onconetix, Inc. compare | −7.3× |
| DCOY Decoy Therapeutics Inc compare | −3.5× |
| GOVX GeoVax Labs Inc. compare | −0.3× |
| SLXN Silexion Therapeutics Corp compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | 0.6× |
| HCWB HCW Biologics Inc. compare | 1.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)